
  
    
      
        PRESENTATION_NNP of_IN CASE_NN
        A_DT 25_CD -_: y-old_JJ woman_NN presented_VBN with_IN pulmonary_JJ embolism_NN ._. She_PRP had_VBD been_VBN taking_VBG ,_, without_IN
        apparent_JJ complication_NN ,_, norgestimate_NN /_NN ethynil_NN estradiol_NN (_( Ortho_NNP Tri-_NNP Cyclen_NNP ;_: 0_CD ._. 180_CD ,_, 0_CD ._. 215_CD ,_, and_CC
        0_CD ._. 250_CD mg_NN norgestimate_NN cycles_NNS and_CC 35_CD μg_NN ethinyl_NN estradiol_NN )_) for_IN 2_CD y_NN ,_, followed_VBN by_IN the_DT same_JJ
        drug_NN combination_NN but_CC with_IN a_DT lower_JJR dose_NN of_IN ethinyl_NN estradiol_NN (_( Ortho_NNP Tri-_NNP Cyclen_NNP Lo_NNP ;_: 25_CD μg_NN
        ethinyl_NN estradiol_NN )_) for_IN 14_CD mo_NN ._. A_DT nonsmoker_NN ,_, she_PRP lacked_VBD a_DT relevant_JJ family_NN history_NN and_CC was_VBD
        vigorously_RB athletic_JJ ._.
        One_CD month_NN prior_RB to_TO presentation_NN ,_, she_PRP developed_VBD neck_NN pain_NN ;_: disc_NN protrusion_NN at_IN C_NNP 5_CD -_: C_NNP 6_CD was_VBD
        detected_VBN by_IN magnetic_JJ resonance_NN imaging_NN ._. The_DT patient_NN was_VBD prescribed_VBN valdecoxib_NN ,_, 20_CD mg_NN twice_RB
        a_DT day_NN (_( b_SYM ._. i_NNP ._. d_SYM ._. )_) ,_, for_IN 2_CD wk_NN ._. Her_PRP$ neck_NN pain_NN resolved_VBN ._. However_RB ,_, towards_IN the_DT end_NN of_IN this_DT
        treatment_NN period_NN ,_, she_PRP developed_VBD left-sided_JJ pleuritic_JJ chest_NN and_CC shoulder_NN pain_NN after_IN a_DT 6_CD -_: h_NN
        car_NN ride_NN ._. She_PRP was_VBD started_VBN on_IN cyclobenzaprine_NN ,_, 10_CD mg_NN b_SYM ._. i_NNP ._. d_SYM ._. ,_, and_CC continued_VBD on_IN valdecoxib_NN ._.
        Her_PRP$ left-sided_JJ pain_NN abated_VBN gradually_RB ._. However_RB ,_, 18_CD d_SYM later_RB ,_, she_PRP developed_VBD right-sided_JJ chest_NN
        and_CC shoulder_NN pain_NN ._. A_DT diagnosis_NN of_IN left_JJ iliac_NN vein_NN thrombosis_NNS and_CC bilateral_JJ pulmonary_JJ emboli_NN
        was_VBD based_VBN on_IN a_DT computed_JJ tomography_NN scan_VB ._. She_PRP was_VBD heparinized_JJ and_CC continued_VBD on_IN therapy_NN with_IN
        warfarin_NN ,_, 5_CD mg_NN b_SYM ._. i_NNP ._. d_SYM ._. ,_, and_CC enoxaparin_NN ,_, 60_CD mg_NN b_SYM ._. i_NNP ._. d_SYM ._. Despite_IN this_DT ,_, a_DT ventilation-perfusion_JJ
        scan_VB performed_VBN 13_CD d_SYM later_RB showed_VBD multiple_JJ pulmonary_JJ emboli_NN (_( Figure_NN 1_LS )_) ._.
        Currently_RB ,_, the_DT patient_NN is_VBZ on_IN warfarin_NN ,_, 2_CD ._. 5_CD mg_NN daily_JJ ,_, while_IN completing_VBG a_DT 6_CD -_: mo_NN warfarin_NN
        regimen_NN ._. Her_PRP$ warfarin_NN is_VBZ well_RB tolerated_JJ and_CC otherwise_RB the_DT patient_NN is_VBZ in_IN good_JJ health_NN ._.
      
      
        DISCUSSION_NNP
        Coxibs_NNP ,_, selective_JJ inhibitors_NNS of_IN cyclooxygenase-_NN 2_CD (_( COX-_NNP 2_LS )_) ,_, increase_NN the_DT risk_NN of_IN
        myocardial_NN infarction_NN and_CC stroke_NN [_NN 1_CD –_NN 3_CD ]_NN ,_, prompting_VBG concern_NN for_IN patients_NNS with_IN established_VBN
        cardiovascular_JJ disease_NN ._. Caution_NN may_MD also_RB extend_VB to_TO individuals_NNS predisposed_JJ to_TO thrombosis_NNS by_IN
        genetic_JJ or_CC environmental_JJ factors_NNS ._.
        Risk_NN factors_NNS for_IN spontaneous_JJ thrombosis_NNS include_VBP oral_JJ contraceptives_NNS ,_, genetic_JJ
        predisposition_NN to_TO a_DT hypercoaguable_JJ state_NN ,_, and_CC prolonged_JJ periods_NNS of_IN stasis_NNS [_NN 4_CD –_NN 6_CD ]_NN ._. At_IN least_JJS
        two_CD risk_NN factors_NNS pertained_JJ to_TO this_DT patient_NN ._.
        The_DT patient_NN had_VBD been_VBN taking_VBG oral_JJ contraceptives_NNS for_IN 3_CD y_NN prior_RB to_TO the_DT index_NN event_NN ,_, albeit_IN
        without_IN recognized_VBN thrombotic_JJ complication_NN ._. It_PRP is_VBZ possible_JJ that_IN despite_IN this_DT extended_JJ
        period_NN of_IN apparent_JJ tolerance_NN ,_, the_DT embolic_JJ events_NNS were_VBD solely_RB related_VBN to_TO use_NN of_IN the_DT oral_JJ
        contraceptives_NNS [_NN 4_CD ]_NN ._.
        The_DT relatively_RB small_JJ risk_NN of_IN venous_JJ thromboembolism_NN attributable_JJ to_TO oral_JJ contraceptive_JJ
        use_NN may_MD interact_NN geometrically_RB with_IN the_DT similarly_RB small_JJ absolute_JJ risk_NN of_IN a_DT procoagulant_NN
        mutation_NN ,_, such_JJ as_IN Factor_NN V_NNP Leiden_NNP [_NN 5_CD ]_NN ._. However_RB ,_, documented_VBN genetic_JJ risk_NN factors_NNS ,_, such_JJ as_IN
        abnormalities_NNS in_IN lupus_JJ anticoagulant_NN ,_, anti-thrombin_JJ III_NNP ,_, proteins_VBZ C_NNP and_CC S_NNP ,_, plasma_NN
        homocysteine_NN ,_, anticardiolipin_NN ,_, β_NN 2_CD glycoprotein_NN antibody_NN ,_, and_CC prothrombotic_JJ mutations_NNS in_IN
        Factor_NN V_NNP and_CC prothrombin_NN were_VBD excluded_VBN ._. It_PRP remains_VBZ possible_JJ that_IN the_DT patient_NN was_VBD
        genetically_RB predisposed_JJ to_TO thrombosis_NNS by_IN a_DT mutation_NN in_IN an_DT undetermined_JJ factor_NN ._.
        Finally_RB ,_, prolonged_JJ stasis_NNS ,_, such_JJ as_IN that_DT which_WDT occurred_VBD during_IN the_DT 6_CD -_: h_NN car_NN trip_NN ,_, may_MD
        account_VB for_IN the_DT clinical_JJ event_NN [_NN 6_CD ]_NN ._. However_RB ,_, the_DT absolute_JJ risk_NN is_VBZ small_JJ ,_, and_CC the_DT patient_NN
        had_VBD made_VBN this_DT trip_NN on_IN multiple_JJ occasions_NNS devoid_JJ of_IN apparent_JJ clinical_JJ complications_NNS during_IN
        the_DT prior_RB 3_CD y_NN ._.
        The_DT risk_NN of_IN thrombosis_NNS from_IN valdecoxib_NN has_VBZ now_RB been_VBN established_VBN [_NN 3_CD ,_, 7_CD ]_NN ,_, and_CC this_DT ,_,
        together_RB with_IN its_PRP$ propensity_NN rarely_RB to_TO cause_VB Stevens-_NNP Johnson_NNP syndrome_NN without_IN a_DT mitigating_JJ
        benefit_NN over_IN traditional_JJ nonsteroidal_NN anti-inflammatory_JJ drugs_NNS ,_, has_VBZ led_VBN to_TO its_PRP$ withdrawal_NN
        from_IN the_DT market_NN
        ._. The_DT cardiovascular_JJ hazard_NN of_IN coxibs_NNS appears_VBZ likely_JJ to_TO be_VB attributable_JJ
        to_TO the_DT suppression_NN of_IN COX-_NNP 2_CD -_: derived_VBN prostacyclin_NN [_NN 1_CD ,_, 8_CD ]_NN ._. Deletion_NNP of_IN the_DT prostacyclin_NN
        receptor_NN in_IN mice_NNS does_VBZ not_RB cause_VB spontaneous_JJ thrombosis_NNS ,_, but_CC rather_RB enhances_VBZ the_DT response_NN to_TO
        thrombotic_JJ stimuli_NNS [_NN 9_CD ]_NN ._. This_DT is_VBZ consistent_JJ with_IN the_DT fact_NN that_IN a_DT cardiovascular_JJ signal_NN from_IN
        a_DT coxib_NN is_VBZ most_RBS easily_RB detected_VBD in_IN patients_NNS with_IN hemostatic_JJ activation_NN ,_, such_JJ as_IN was_VBD
        observed_VBN under_IN placebo-controlled_JJ conditions_NNS in_IN two_CD trials_NNS in_IN patients_NNS undergoing_VBG
        cardiopulmonary_JJ bypass_NN grafting_VBG [_NN 7_CD ]_NN and_CC anecdotally_RB in_IN patients_NNS with_IN connective_JJ tissue_NN
        disease_NN [_NN 10_CD ]_NN ._.
        Although_IN this_DT case_NN does_VBZ not_RB establish_VB a_DT causative_JJ linkage_NN with_IN valdecoxib_NN ,_, the_DT clinical_JJ
        event_NN was_VBD not_RB manifest_JJ until_IN three_CD potential_JJ risk_NN factors_NNS were_VBD combined_VBN (_( oral_JJ
        contraceptives_NNS ,_, prolonged_JJ stasis_NNS ,_, and_CC coxib_NN treatment_NN )_) ._. Given_VBN the_DT multiplicative_JJ
        interactions_NNS of_IN risk_NN factors_NNS for_IN thromboembolic_JJ disease_NN and_CC the_DT apparently_RB untoward_NN
        concurrence_NN of_IN two_CD of_IN them—the_NN contraceptive_JJ pill_NN and_CC frequent_JJ road_NN trips_NNS for_IN the_DT preceding_VBG
        3_CD y—the_NN rapid_JJ occurrence_NN of_IN the_DT clinical_JJ event_NN following_VBG initiation_NN of_IN the_DT coxib_NN suggests_VBZ a_DT
        causative_JJ link_NN to_TO the_DT COX-_NNP 2_CD inhibitor_NN ._. However_RB ,_, it_PRP also_RB remains_VBZ formally_RB possible_JJ that_IN this_DT
        temporal_JJ relationship_NN was_VBD a_DT coincidence_NN ._.
        This_DT case_NN report_NN has_VBZ been_VBN reported_VBN to_TO the_DT regulatory_JJ authorities_NNS and_CC to_TO the_DT manufacturer_NN
        of_IN valdecoxib_NN ._.
        Just_RB as_IN the_DT small_JJ absolute_JJ risks_NNS of_IN thrombosis_NNS attributable_JJ to_TO oral_JJ contraceptives_NNS and_CC
        prothrombotic_JJ mutations_NNS may_MD interact_NN dramatically_RB [_NN 5_CD ]_NN ,_, selective_JJ inhibitors_NNS of_IN COX-_NNP 2_CD may_MD
        also_RB interact_NN with_IN genetic_JJ and_CC environmental_JJ factors_NNS that_WDT predispose_VB to_TO the_DT risk_NN of_IN
        thrombosis_NNS ._.
      
    
  
